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The present study focused on inhibition of HSV-1 and -2 replication and pathogenesis in vitro and 
in vivo, through the selective targeting of the envelope glycoprotein D. Firstly, a human 
monoclonal antibody (Hu-mAb#33) was identified that was able to neutralise both HSV-1 and -2 at 
nanomolar concentrations, including clinical isolates from patients affected by different clinical 
manifestations and featuring different susceptibility to acyclovir in vitro. Secondly, the potency of 
inhibition of both infection by cell-free viruses and cell-to-cell virus transmission was also 
assessed. Finally, mice receiving a single systemic injection of Hu-mAb#33 were protected from 
death and severe clinical manifestations following both ocular and vaginal HSV-1 and -2 lethal 
challenge. These results pave the way for further studies reassessing the importance of HSV entry 
as a novel target for therapeutic intervention and inhibition of cell-to-cell virus transmission. 
 
Highlights:  
 HSV-1 and -2 cross-protection is conferred in vivo by single post-infection systemic 
administration of a human anti-gD mAb 
 This inhibitory activity of mAb results also in the inhibition of cell-to-cell virus transmission 
 Fab#33, scFv#33 and IgG#33 engineered molecular formats of anti-gD mAb exert different 
anti-viral activity 
 HSV-1 and -2 clinical isolates are more susceptible to mAb activity compared to reference 
virus laboratory strains 
 





The global prevalence of HSV-2 is approximately 67%, lower than HSV-1. Nevertheless, HSV-2 still 
infects 19.2 million people every year with at least 3.4 million women infected in Africa (Looker et 
al., 2015). Thus, even a tiny proportion of severe HSV infections is a healthcare burden. Despite 
the availability of effective drugs, clinical isolates can be resistant to both first and second line 
drugs (acyclovir (ACV) and foscarnet (FOS), respectively) (Andrei and Snoeck, 2013; Schubert et al., 
2014). The observed prevalence of ACV-resistant HSV in immunocompetent individuals is 0.1-
0.6%, while FOS resistance has been found in about 60% of patients infected with these ACV-
resistant viruses (Gilbert et al., 2002; Lascaux et al., 2012). All the available drugs exhibit 
nephrotoxicity when administered at high doses, thus limiting their clinical use in patients with 
impaired kidney function (Superti et al., 2008; Whitley and Roizman, 2001). Novel alternative or 
synergistic therapies are needed (Clementi et al., 2016), especially for the management of high 
risk patients such as new-borns, immunocompromised or post-transplant patients (Cherpes et al., 
2012; Grinde, 2013; Whitley, 2006). Moreover, in immunocompromised patients the prevalence of 
ACV resistance increases to 4.3-14% (Gilbert et al., 2002). In this context inhibition of HSV entry 
may represent an additional therapeutic target. Among the classes of virus entry inhibitors the  
monoclonal antibodies (mAbs) are particularly versatile and have the advantage that their 
different engineered formats (single chain fragment variable (scFv), Fab fragment and whole-IgG) 
can meet both pharmacokinetic and pharmacodynamic needs while retaining their specificity for 
the target (Jefferis, 2012; Marasco and Sui, 2007), in addition, the use of human Abs generally 
reduces the risk of eliciting antidrug antibodies after administration in humans (Clementi et al., 
2012; Presta, 2006). To date, several anti-HSV neutralising mAbs have been described (Berdugo et 
al., 2012; Burioni et al., 1994; Chen et al., 2004; Krawczyk et al., 2013; Lee et al., 2013; Nicola et 
al., 1998), but only a few are human-derived and inhibition of HSV infection by different 
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engineered antibody formats (Fab, scFv, IgG) has never been compared. In the present study, an 
anti-HSV Hu-mAb (mAb#33) was isolated and its different formats (Fab#33, scFv#33, IgG#33) were 
tested for their ability to inhibit virus infection both before and after virus entry (post-virus entry 
assays) using clinical isolates representing HSV-1 and HSV-2 with differing susceptibility to ACV. 
Finally, the mAb#33 format with the greatest potency in vitro was also tested in vivo using single 
systemic administrations against HSV-1 or -2 vaginal and ocular infections. 
 
2. Materials and methods  
2.1 Cells and Viruses 
Vero E6 (Vero C1008, clone E6 - A TCC® CRL-1586TM) and HEK 293T (ATCC® CRL-1586TM) cells 
were both cultured in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% (v/v) fetal 
bovine serum (FBS). The laboratory strains HSV-1 HF (ATCC® VR-260™) and HSV-2 MS (ATCC® VR-
540™) were used. Clinical isolates were kindly provided by Dr. R. Santangelo, Department of 
Microbiology, Università Cattolica del Sacro Cuore of Rome, Italy. The HSV-1 LV strain has been 
previously described (Tognon et al., 1985).  
2.2 Mice 
Female C57BL/6N mice, 8 weeks of age, were purchased from Charles River Laboratories (Sulzfeld, 
Germany) and housed and bred in a biosafety level 3 animal facility. Animals were maintained on 
12/12-h dark/light cycle. Animal experiments were reviewed and approved by OPBA (Organismo 
Preposto al Benessere Animale) Università di Pisa and Ministero della Salute (Permit Number: n° 
603/2015-PR) by the responsible authority DGSAF (Direzione Generale della Sanità Animale e dei 
Farmaci Veterinari), according to Italian Welfare Act (D.lgs. 26/2014. Art.31) and European 
regulations (2010/63/EU).  
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2.3 Generation and production of Fab#33 
Fab#33 was selected using phage-display (Johnston et al., 2011; Solforosi et al., 2012). Briefly, a 
phagemid library was constructed from peripheral B cells of a donor showing strong serum IgG 
ELISA reactivity against both HSV-1 and -2 isolates. Fab#33 was selected against HSV-1 and -2 
infected Vero E6 cells after deselection against uninfected cells, and subsequently affinity purified 
through a GammaBind Sepharose (GE Healthcare) column with goat anti-Human IgG Fab 
(ThermoFisher Scientific). 
2.4 Other antibodies 
The anti-HSV gD positive neutralisation control human Fab AC-8 (Burioni et al., 1994) was 
synthesised using its previously published amino acid sequence (Berdugo et al., 2012). Anti-HCV E2 
e137 human mAb was used as negative experimental control (Perotti et al., 2008). 
2.5 scFv#33 and IgG#33 
scFv#33 was constructed using overlapping primers with the 15-amino acid (Gly4Ser)3 flexible 
hinge region respectively at 3’ and 5’, and purified following previously described protocols. 
IgG#33 format was designed in our laboratory using the IgG1 constant region, and the large-scale 
production was performed by GenScript® using MamPower service. Briefly, target DNA were 
designed, synthesised and subcloned into pTT5 vectors for 293-6E cells co-transfection and 
expression. The cell supernatant was collected and affinity purified. 
2.6 Neutralisation assays and post-entry inhibition assays  
The biological activity of mAbs was determined in vitro using three different strategies.  
2.6.1 Plaque assay 
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Serial concentrations of the different antibody formats were incubated with 100 plaque forming 
units (PFU) of virus (1 h at 37°C) in DMEM. Antibody-virus mixture was applied to Vero E6 
monolayers. After 2 h, medium was replaced with complete DMEM with 2 % FBS and 1 % Agarose 
(BD) and plates were incubated for 46 h. Cells were then fixed and stained.  
2.6.2 IN Cell Analyzer System analysis 
Different antibody concentrations were incubated with 200 TCID50 of virus for 1 h at 37 °C. 
Virus/antibody mixture was applied to Vero E6. After 2 h, medium was replaced with complete 
DMEM with 2 % FBS and plates were incubated for 21 h. Cells were fixed and stained with anti-
HSV1+HSV2 gD murine antibody [2C10] (ab6507, Abcam) and Goat anti-Mouse IgG–FITC antibody 
(F0257, Sigma-Aldrich). Hoechst 33258 (Sigma-Aldrich) was used for nuclear staining. IN Cell 
Analyzer System allowed high-throughput acquisition and analysis was performed using IN Cell 
Investigator Software (Galluccio et al., 2014; Ranade et al., 2014). 
2.6.3 Post-entry assay 
The post-entry assay was adapted from Krawczyk et al., 2013 and De Logu et al., 1998 (De Logu et 
al., 1998; Krawczyk et al., 2013). Confluent monolayers of Vero E6 were infected with 100 PFU of 
virus. After 20 min of adsorption at 37°C, the virus was removed. Cells were then incubated for 46 
h in DMEM containing 2 % FBS and 1 % Agarose in the presence of different mAb concentrations. 
Cells were fixed and stained. Images were acquired at 5-fold magnification. Viral plaques were 
counted and areas measured in silico using ImageJ 1.50c4 software (Rasband, ImageJ, U.S.N.I.H., 
Bethesda USA, http://imagej.nih.gov/ij/). 
2.7 Cytofluorimetric binding assays 
The binding activity of Fab#33 was assayed using HEK 293T cells transfected with glycoprotein D 
from HSV-1 HF (gD1) as described in the Supplementary Materials. After centrifugation cells were 
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fixed with 4 % paraformaldehyde and incubated for 30 min at room temperature with Fab#33 in 
presence or absence of the competitor anti-HSV gD AC-8 Fab (Burioni et al., 1994). Additionally, 
unrelated anti-HCV E2 e137 Fab (Perotti et al., 2008) was used as negative control as well as 
untransfected cells. The cells were then washed and incubated for 30 min at room temperature 
with goat anti-human IgG (H+L) Alexa Fluor® 488 (A-11013, ThermoFisher Scientific) or FITC-
conjugated anti-FLAG [M2] (F4049, Sigma-Aldrich) antibodies. Afterwards, the cells were washed 
and analyzed by FACS. The FACS data were analyzed using FCS Express 6 Plus software (De Novo 
Software).  
2.8 In vivo virus titration  
In vivo titration via vaginal challenge of HSV-2 MS viral stock was performed in mice at 11 weeks of 
age, with their oestrous cycles synchronized (Teepe et al., 1990). Ten-fold dilutions of the viral 
stocks in DMEM (50 μL) were pipetted intravaginally under general anaesthesia. HSV-1 LV and 
HSV-2 MS viral stocks were used for in vivo titration via ocular challenge: under general 
anaesthesia, the right cornea was scarified and 5 μL of DMEM (2 % serum) containing 10-fold 
dilutions of the viral stocks was applied. The animals were then examined daily for apparent signs 
of infection. The lethal dose 50 (LD50) of both viruses was assessed for each infection protocol (Fig. 
S10). The doses of both viruses for the different infection protocols were determined by 
observation of irreversible symptoms at day 8 post infection (p.i.) for HSV-2 MS (both for vaginal 
and ocular challenge) and at day 13 p.i. for HSV-1 LV. Mice that recovered from disease were 
followed up for 20 days p.i. and no relevant differences in their conditions, nor delayed onset of 
clinical symptoms were observed. 
2.9 IgG#33 prophylactic and therapeutic activity against vaginal challenge  
2.9.1 In vivo virus infections and treatments.  
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Eleven week old female mice were infected with 50 L of HSV-2 MS (5x107 PFU) diluted in DMEM. 
Mice received 100 L of IgG#33 (5 or 15mg/kg) diluted in PBS via lateral tail vein as a single dose 
24 h before or 30 min after vaginal challenge. Anti-HCV IgG e137 (15mg/kg) was used as negative 
control. Groups consisted of 7 mice each, animals were sacrificed on day 8 to avoid unnecessary 
suffering. Animal experiments were approved by Pisa University and Ministry of Health, 
accordingly to national and European regulations (2010/63/EU).  
2.9.2 Clinical disease scoring  
Severity of genital lesions was scored as previously described (Chiuppesi et al., 2012). Animals 
were scored at baseline and at daily intervals. Clinical scores were reported starting from the 
onset of symptoms to the end of protocol (day 5 to 8).  
2.9.3 Vaginal lavage viral titres 
At 48 h post-challenge mice were anesthetised, the vaginas were flushed with 50 µL of 1X PBS  and 
the lavages stored at -80 °C. Subsequently, 10 µL of vaginal lavage were applied to Vero E6 cell 
monolayers. After 2 h, inoculum was replaced with complete DMEM with 2% FBS and plates 
incubated for 21 h. Cells were fixed, stained and analysed using IN Cell Analyzer. 
2.10 IgG#33 therapeutic activity against ocular challenge 
2.10.1 In vivo virus infections and treatments 
Under general anaesthesia, the right cornea was scarified (Berdugo et al., 2012). 5 L of HSV-1 LV 
(5 x 104 PFU) or HSV-2 MS (5 x105 PFU) diluted in DMEM was applied to scarified cornea. Eleven 
week old female mice received 100 L of IgG#33 (15 mg/kg) i.v., or IgG e137 (15 mg/kg) as 
controls, diluted in 1X PBS via lateral tail vein as a single dose 30 min after infection. All groups 
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consisted of 5 mice each and all HSV-1 infected mice were sacrificed on day 13, while HSV-2 
infected mice were sacrificed on day 8 to avoid unnecessary suffering.   
2.10.2 Clinical disease scoring 
The severity of ocular disease was scored as previously described (Berdugo et al., 2012). Animals 
were scored at baseline and daily.  
2.10.3 Tear film viral titres 
At 2nd and 7th day p.i. mice were anesthetized and infected corneas were flushed pipetting and 
recollecting 10 L of DMEM containing 2 % serum (Berdugo et al., 2012). The tear film content 
was added to 190 L of medium, stored at -80 °C and analysed as for vaginal lavages. Moreover, 
10 µL of tear film samples were used for viral DNA extraction (QIAGEN) and genomic copies 
quantified using ELITeMGB® Kit (ELITechGroup) for Real-Time PCR analysis.  
2.10.4 Tissue preparation and Immunohistochemistry  
Kidneys and eyes from each group were dissected, fixed and mounted in Killik (Bio-Optica) at -80 
°C for cryosectioning. Frozen cryosections were rinsed, incubated in 0.1% Triton X-100, blocked 
with 1% BSA (Sigma-Aldrich), and incubated overnight at 4°C with anti-HSV1+HSV2 gD antibody 
[2C10] (ab6507, Abcam). Samples were incubated for 1 h at 20 °C with Goat anti-Mouse IgG (H+L) 
Alexa Fluor 546® (A-11030, ThermoFisher Scientific) and Alexa Fluor 488® Phalloidin (A12379, 
ThermoFisher Scientific). Hoechst was used for nuclear staining. Slides were observed at 63- and 
10-fold magnification. 
2.11 Statistical analysis  
All data analyses and statistics were performed using GraphPad PRISM® (GraphPad Software, San 
Diego California USA, www.graphpad.com). One-way ANOVA was performed for repeated 
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measures followed by Bonferroni post-test was performed for the evaluation of plaque area 
inhibitory activity of the different Hu-mAb#33 engineered formats. The same test was performed 
for the comparison of reduction of plaque number of the different mAb engineered formats in 
post-entry assays. Kaplan-Meier survival curves were compared using the log-rank (Mantel-Cox) 
test considering p value 0.05 as threshold for statistical significance. Two-way ANOVA with 
Bonferroni post-tests were used to perform statistical comparisons between the different mean 
disease clinical scores observed for each treated mouse cohort. One-way ANOVA followed by 
Kruskal-Wallis test was used for statistical analysis of data generated by titres of vaginal lavages. T-
test followed by Welch’s correction was used for statistical analysis of data generated by titres and 
genomic copies quantification assays of tear film samples. 
See Supplementary for fully detailed Material and Methods 
 
3. Results 
Prior to choosing the antibody format to be evaluated in animal infection models, the Hu-mAb#33 
was produced in three different molecular formats: Fab, scFv and IgG. After the identification of 
the virus glycoprotein recognised by Hu-mAb#33, all the three formats were first tested for their 
ability to neutralise viruses belonging to both HSV-1 and 2, including clinical isolates with different 
susceptibility to ACV in in vitro phenotypic assays. Their inhibitory activity was tested in a newly 
developed post-entry assay performed at 37 °C, allowing virus entry into target cells to test the 
ability of scFv#33, Fab#33 and IgG#33 to inhibit virus replication and even more importantly, cell-
to-cell transmission, when added after virus infection in semi-solid culture medium. Based on the 
lower IC50 and potent post-entry inhibitory activity compared to other molecular formats, Hu-
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mAb#33 IgG was chosen for testing in vivo its capability to protect mice from lethal virus vaginal 
and ocular HSV-1 and -2 virus challenge. 
3.1 Generation of an anti-HSV-1 and HSV-2 cross-reactive Hu-mAb and target identification 
A Hu-mAb was generated as Fab fragment (Fab#33) using optimised biopanning procedures from 
peripheral B-lymphocytes of a donor showing strong serum IgG reactivity in ELISA against HSV-1 
and -2 isolates (Fig. S1). Fab#33 selectively recognised HSV-1 HF- and HSV-2 MS-infected cells (Fig. 
S2A). Western-blotting (WB) analysis on purified HSV-1 particles (Fig. S3A) and indirect 
immunofluorescence (IIF) analysis on cells transfected with HSV-1 HF gD or HSV-1 HF gB (Fig. S3B) 
were also performed. Both assays demonstrated the specific binding of Fab#33 only on gD-
transfected cells. 
3.2 Evaluation of anti-HSV neutralising activity 
Fab#33 neutralising activity was assessed by plaque reduction assays (PRA) against both HSV-1 and 
-2. Fab#33 The IC50 values against HSV-1 HF and HSV-2 MS were calculated to be 0.76µg/mL and 
0.118µg/mL, respectively. Fab#33 potency was also determine by micro-neutralisation assay 
followed by automated IIF counting,  with IC50 values of 0.612 µg/mL for HSV-1 HF and 0.135 
µg/mL for HSV-2 MS (Fig. S4, S5, Table 1). Both assays confirmed that Fab#33 neutralises both HSV 
types at low nanomolar concentrations: 2.7nM (HSV-2 MS) and 12.24nM (HSV-1 HF). 
3.3 Evaluation of post-entry inhibitory activity 
The ability of Fab#33 to inhibit replication of HSV-1 and -2  even after infection was evaluated 
using a specifically adapted PRA in which the Fab#33 was dissolved in low concentration DMEM-
agar medium. Both number and area of plaques were quantified. Fab#33 reduced the number of 
HSV-1 HF plaques by 18.92 % and HSV-2 MS plaques by 57 % at 50 and 200 µg/mL (Krawczyk et al., 
2013) (Fig. 1A). Fab#33 reduced the mean plaque area by 43.5 %, even at 100 µg/mL on HSV-2 
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MS-infected cells, whereas no significant reduction in plaque area was observed on HSV-1 HF-
infected cells (p>0.05) (Fig. 1B). Fab#33 post-entry activity was also compared with that of anti-
HSV Hu-Fab AC-8, already described for its neutralising activity against both HSV-1 and -2 (Berdugo 
et al., 2012; Burioni et al., 1994; De Logu et al., 1998) (Fig. 1A, B). No significant differences 
between the two Fabs were observed in reduction of plaque number for HSV-2 MS infection 
(p>0.05), while only Fab#33 slightly decreased the number of plaques on HSV-1 HF infected cells 
(p<0.05). No differences were observed in plaque area reduction for HSV-1 HF. Interestingly, 
Fab#33 exhibited greater potency than AC-8 against HSV-2 MS (43.5% reduction by 100µg/mL 
Fab#33, vs 24.3% reduction by 200µg/mL AC-8) (Fig. 1A, B). A competition assay between the two 
Fabs was also performed by FACS analysis of cells transfected with gD1. Some competition, 
decreasing in a dose-dependent manner, was observed at higher AC-8 concentration (10 μg/mL) 
using Fab#33 at low concentration (1.5 μg/mL) for all the tested AC-8 concentrations (Fig. 1C).   
3.4 Evaluation of in vitro activity of different engineered Hu-mAb#33 formats: scFv#33, Fab#33 
and IgG#33 
To evaluate the biological activity of different antibody formats, scFv#33, Fab#33 and IgG#33 
formats were produced and tested for their ability to bind, neutralise and inhibit HSV post-entry 
replication. Both IgG#33 and scFv#33 bound to cells infected with HSV-1 HF or HSV-2 MS isolates 
(Fig. S2B) Comparison of their neutralising activity revealed that IgG#33 possessed IC50s of 
1.092µg/mL (HSV-1 HF) and 0.731µg/mL (HSV-2 MS) (Table 1, Fig. S5). No appreciable neutralising 






 IC50 g/mL (nM) 
 ScFv#33 Fab#33 IgG#33 
HSV-1 HF >10 (400) 0.612 (12.24) 1.092 (7.28) 
HSV-2 MS >10 (400) 0.135 (2.7) 0.731 (2.44) 
 
Table 1. Neutralising activity of different Hu-mAb#33 engineered formats.  
 
scFv#33 and IgG#33 inhibition of HSV infection was then assessed using the adapted PRA (Fig. 2A, 
B and S7A, B and S8A, B). In this case, scFv#33 in semi-solid medium inhibited the number of 
infectious events by 29.6 % on HSV-2 MS infected cells at 200 µg/mL and by 24.2 % at 50 µg/mL. 
scFv#33 inhibited the number of infection HSV-1 events by 22.16 % at 50 µg/mL. In contrast, 
IgG#33 strongly inhibited HSV-2 MS infection events in a dose-dependent manner spanning from 
93 % inhibition at 100 µg/mL, to 40 % inhibitory activity at the lowest tested concentration (6 
µg/mL). No significant inhibition of viral events (6.57 %) was observed for IgG#33 format against 
HSV-1 HF at the highest concentration (25 µg/mL). Both scFv#33 and IgG#33 formats potently 
reduced HSV-2 MS plaque areas in a dose-dependent manner. scFv#33 inhibited virus spreading 
by 99.8 % at 200 µg/mL and plaque area was inhibited by 90 % at 100 µg/mL and by 63.2 % at 12.5 
µg/mL. IgG#33 almost completely eliminated plaque area (98.2 % reduction) of HSV-2 MS at 100 
µg/mL and by 44.2 % at 6 µg/mL. scFv and IgG formats inhibited HSV-1 HF virus cell-to-cell spread 
by 91.7 % at 50 µg/mL and 94.2 % at 25 µg/mL respectively.  
3.5 Evaluation of IgG#33 anti-HSV activity against HSV-1 and 2 clinical isolates 
The cross-protection conferred by IgG#33 was evaluated against different clinical isolates from 
patients with different clinical manifestations: #1 (oral lesions), #8 (pharyngeal swab), #7 
(bronchoalveolar lavage), #11 (labial vesicles), #LV (neurotropic strain (Tognon et al., 1985)) for 
HSV-1, and #18 (cutaneous lesions), #21 (vaginal discharge) #25 (vaginal lesions), #26 (cutaneous 
lesions) and #28 (cutaneous lesions) for HSV-2. All the isolates featured different susceptibility to 
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ACV (Fig. S9). As depicted by Table 2 and Fig. S6, IgG#33 was able to potently neutralise all tested 
clinical isolates at very low IC50.  
HSV-1 IgG#33 IC50 g/mL (nM) HSV-2 IgG#33 IC50 g/mL (nM) 
HF 1.092 (7.28) MS 0.731 (2.44) 
#1 0.306 (2.04) #18 0.696 (4.64) 
#7 0.741 (4.94) #21 0.519 (3.46) 
#8 0.632 (4.21) #25 0.379 (2.53) 
#11 0.558 (3.72) #26 0.463 (3.09) 
LV 0.436 (2.91) #28 0.656 (4.37) 
 
Table 2. Neutralising activity of IgG#33 vs HSV clinical isolates featuring different susceptibility 
to ACV in vitro.  
 
IgG#33 post-entry activity was evaluated against LV and #26 virus isolates (Fig. 3A, B). IgG#33 
inhibited the number of plaques of HSV-1 LV by 76.85 % at 25µg/mL (p<0.05), and by 45.68 % at 3 
µg/mL (p<0.05). IgG#33 showed even greater activity against HSV-2 #26, showing 94.18 % 
inhibition at 100 µg/mL and 52.13 % inhibition at 10 µg/mL (p<0.05). IgG#33 reduced plaque areas 
by 98 % at 100 µg/mL on HSV-2 #26 and by 75.3 % at 25 µg/mL on HSV-1 LV. 
3.6 Prophylactic and therapeutic activity of IgG#33 against vaginal HSV-2 challenge 
A single systemic injection of IgG#33 (5 mg/Kg or 15 mg/Kg) via lateral tail vein was performed 24 
h prior or 30 min post HSV-2 MS infection (30 minutes are sufficient for virus entry (Vahlne et al., 
1980)). Kaplan-Meier survival curves (Fig. 4A) revealed that both IgG#33 dosages conferred 100 % 
protection from death (7/7 mice survived) 8 days p.i., compared to control groups in both settings 
(5/7 mice died; 71.43% mortality) (p=0.0075). No statistical difference at day 8 p.i. (p=0.1356) was 
observed between negative control IgG treated mice (2/7 mice died) and infection control (5/7 
mice died) in prophylactic protocol, while in a therapeutic setting 6/7 mice died in the unrelated 
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IgG mock control group (p=0.0019). The mean clinical disease scores revealed that both IgG#33 
single doses strongly inhibited clinical manifestation of HSV-2 infection compared to infection and 
mock controls (Fig. 4B). Clinical scores were reported from the onset of symptoms to the end of 
protocol (day 5 to 8). Mean clinical disease scores of prophylactic protocol were: 1.571 to 2.857 
for HSV-2 infection control group; 0.643 to 2.114 for the group receiving unrelated IgG; 0.143 to 
0.286 for IgG#33 5 mg/Kg; and 0 to 0.571 for the group receiving 15 mg/Kg IgG#33. Mean clinical 
disease scores of therapeutic protocols were: 1.571 to 2.857 for HSV-2 infection control group; 
1.357 to 3.643 for the group receiving unrelated IgG; 0.143 to 0.286 for the group receiving 5 
mg/Kg IgG#33 and 0.143 to 0.357 for the group receiving 15 mg/Kg IgG#33. Both IgG#33 
concentrations significantly reduced mean disease score compared to virus infection control 
starting from day 6 p.i. (p<0.05) as well as to the group receiving the unrelated IgG (p<0.01). Mice 
treated with IgG#33 in both experimental settings did not present clinically relevant 
manifestations of HSV-2 infection, whereas symptoms in control animals spanned from erythema 
and ulcers to nervous system involvement (Fig. 4C). Finally, vaginal lavages collected 48 h p.i. from 
the different mouse cohorts were tested for their infectious viral load using cell-based infection 
assays (Fig. 4D). A significant reduction in viral load was observed in lavages collected from 
IgG#33-treated groups compared to untreated groups (p<0.01). Titres (FFU/mL) detected in 
vaginal lavages of prophylactic protocol mice were: 7.7 x 105 in the virus infection control group, 
1.2 x 105 in the IgG#33 (5 mg/Kg)-treated group, 6.4 x 104 in the IgG#33 (15 mg/Kg) group and 6.4 x 
105 in the unrelated IgG group. For therapeutic protocol groups were: 7.7 x 105 in the virus 
infection control group, 2.7 x 104 in the IgG#33 (5mg/Kg) group, 1.9 x 104 in the IgG#33 (15mg/Kg) 
group and 2.2 x 105 in the unrelated IgG (15mg/Kg) treated group . p values are reported in Fig. 4. 
3.7 Therapeutic activity of IgG#33 against HSV-1 and HSV-2 ocular challenge 
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A single systemic administration of IgG#33 (15mg/Kg) was performed 30 min after HSV-1 LV 
(neurotropic strain) or HSV-2 MS ocular infections, fully protecting mice from death (Fig. 5A). All 
HSV-1 infected mice were sacrificed on day 13, while HSV-2 infected mice were sacrificed on day 
8, to avoid unnecessary suffering. Specifically, IgG#33 conferred 100% protection (7/7 mice alive) 
at 13 days p.i. against HSV-1 LV in contrast to 71.43% mortality rate (5/7 mice died) observed for 
control groups (p=0.007). IgG#33 fully protected mice (7/7 alive) against HSV-2 MS compared to 
controls (p=0.022 vs virus infection control, and p=0.007 vs unrelated IgG). No differences were 
observed between virus control and an unrelated IgG groups (p=0.590). Mean clinical disease 
scores (Berdugo et al., 2012) were evaluated between days 1-8 p.i. (Fig. 5B). For HSV-1 LV 
protocol, mean of symptom scores were evaluated between days 1-13 p.i.: 0 to 3.714 for virus 
control group; 0 to 4.571 for unrelated IgG and 0 to 0.143  for IgG#33-treated mice, indicating 
almost complete protection conferred by IgG#33 from ocular HSV-1 infection compared to 
controls (p<0.001 from day 8). Mean clinical scoring of HSV-2 MS infections were: 0 to 3.929 for 
the virus control group; 0 to 4.643 for unrelated IgG, and 0.071 to 0.214 for IgG#33-treated mice. 
Mice receiving IgG#33 were significantly protected from HSV-related severe disease compared to 
controls. Mice receiving IgG#33 occasionally developed milder symptoms after HSV-infection but 
they completely recovered from them. In contrast, control mice developed severe movement 
impairment indicating neural involvement and severe HSV ocular symptoms (Fig. 5C). Virus titres 
and quantification of HSV genome copies on tear films collected on days 2 and 7 p.i. were also 
evaluated (Fig. 5D): titres (FFU/mL) in tear samples of mice challenged with HSV-1 and receiving 
IgG#33 were 1.2 x 104 at day 2, and 7.9 x 102 at day 7; 4.3 x 104 infected cells at day 2 and 1.4 x 104 
at day 7 were observed for the unrelated IgG tear samples. In mice infected with HSV-2 titres 
(FFU/mL) were: 5.4 x 103 at day 2 and 1.1 x 102 at day 7 for IgG#33 cohort, and 1.2 x 104 at day 2 
and 1.5 x 103 at day 7 for mice receiving control IgG. The same samples were also tested for the 
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presence of HSV genomes. The median number of genome copies for mice challenged with HSV-1 
were: 272.4 Nc(gEq/µL) at day 2 and 0 Nc(gEq/µL) at day 7 for mice receiving IgG#33; 1783 
Nc(gEq/µL) at day 2 and 17.71 Nc(gEq/µL) at day 7 for mice receiving unrelated IgG. The median 
number of genome copies for mice challenged with HSV-2 were: 3241 Nc(gEq/µL) at day 2 and 0 
Nc(gEq/µL) at day 7 for mice treated with IgG#33; 733.2 Nc(gEq/µL) at day 2 and 182.9 Nc(gEq/µL) 
at day 7 for unrelated IgG controls. Only IgG#33-treated mice completely cleared viral DNA and 
infectious viral load in tear films within 7 days for both HSV challenges. Of note, the viral load was 
nearly undetectable in lavages of IgG#33-treated mice at day 7 p.i.. p values are reported in Fig. 5. 
 
3.8 Histological analyses 
Four kidney anatomical compartments (capsule, cortex, medulla, pelvis) of mice treated with 
IgG#33 or unrelated IgG control after HSV ocular infections were analysed (Fig. 6A). Mice receiving 
systemic IgG#33 presented normal tissue architecture for all the anatomic compartments, while 
mice receiving unrelated IgG control possessed altered tissue architecture, especially for medulla 
and pelvis. With the exception of the capsule, tissues dissected from control mice were found to 
possess virus. Eyes dissected from IgG#33-treated mice and unrelated IgG control group were 
analysed, but no morphological differences were detectable. However, higher virus prevalence 
was detected in all compartments belonging to HSV-1 control cohort (Fig. 6C) compared to mice 
treated with IgG#33 (Fig. 6B), in which virus was restricted to its entry route (cornea) leaving the 
retina almost virus-free. Unfortunately, eye cryosections of mice challenged with HSV-2 MS were 





We investigated, both in vitro and in vivo, the anti-viral activity of an anti-gD human monoclonal 
antibody, mAb#33. The mAb was engineered in three different antibody formats (scFv, Fab, IgG) to 
compare both neutralising activity and ability to inhibit cell-to-cell transmission of both HSV type 1 
and 2. This informed the choice of the best candidate to be administered in mice receiving lethal 
HSV challenge. 
The neutralising activity of the Fab fragment was evaluated against HSV for the first time, by 
micro-neutralisation assay coupled with InCell Analyzer automated count, allowing  fine evaluation 
of Fab IC50 due the ability to test more experimental conditions and more replicates in the same 
experimental session, reducing experimental variability. Results from this assay were also 
confirmed by standard PRA. To the best of our knowledge the IC50 calculated for Fab#33 against 
HSV-1 and -2 are amongst the lowest described so far for Fabs of human origin. It is important to 
highlight, however, that potent neutralising activity does not always translate to good in vivo 
efficacy (De Logu et al., 1998; Dimmock, 1993). In the case of HSV a low IC50, while indicative of 
function, is not the only anti-viral effect to be evaluated. It is well known that HSV infects cells 
both as cell-free virus and via cell-to-cell transmission mechanism. The latter can be barely 
affected even by a neutralising antibody since the virus passes through cell junctions without 
release from infected cells. As such we evaluated the inhibitory activity of Fab#33 even when 
added to cells after virus infection performed at 37°C in semi-solid medium, minimising the 
infection events due to cell free virus. To do this we adapted the post-virus entry assay described 
by Krawczyk et al., 2013 and De Logu et al., 1998 (De Logu et al., 1998; Krawczyk et al., 2013) to 
assess the inhibitory activity of the tested molecules the cell-to-cell transmission. In these 
experiments we also included as a control the human anti-gD Fab better characterised for its 
biological activity so far, the AC-8 (Berdugo et al., 2012; Burioni et al., 1994; De Logu et al., 1998; 
Sanna et al., 1996; 1999; 2000; Zeitlin et al., 1996). The post-entry assays revealed greater activity 
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of the Fab in reducing both number and area of plaques for HSV-2 MS compared to that observed 
against the HSV-1 HF laboratory strain, where only the number of plaques was slightly reduced, 
and in sharp contrast, no reduction in plaque area occurred. The broad activity of Fab#33 against 
HSV-1 HF and HSV-2 MS might be due to the differences in terms of amino acid substitutions 
between the two virus laboratory strains (Fig. S13), potentially impairing Fab affinity. This is also 
consistent with the higher Fab#33 IC50 against HSV-1 HF compared to that against HSV-2 MS. 
These observations for Fab#33  are similar to that of the control mAb AC-8 against the same virus 
isolates, the only exception being the total lack of plaque number reduction by AC-8 Fab against 
HSV-1 HF strain. Additionally, the overall similar behaviour of Fab#33 and AC-8 in post-entry 
assays is also consistent with the reported IC50 of AC-8 against HSV-2 , lower than those described 
against HSV-1. This is supported by the competition observed in FACS analyses performed 
between the two Fabs. As briefly introduced above, the Fab#33 was also engineered in other two 
antibody formats: the scFv and the whole IgG1 tested for both neutralising activity and inhibition 
of virus replication after virus entry. Unexpectedly, despite IgG#33 potently neutralising both HSV-
1 and -2, including clinical isolates featuring reduced susceptibility to acyclovir, the scFv format did 
not show any neutralising activity at the highest concentration tested (IC50>10µg/mL). The same 
scFv potently reduced plaque area for both HSV-1 and -2 but had limited impact on plaque 
number. Accordingly, IgG#33 potently inhibits plaque area for both virus types, consistent with its 
potent inhibition of HSV-2 plaque number but discordant with its weak inhibition of HSV-1 plaque 
number. As observed above for Fab format, the different activity in post-entry assays might be 
due again to differences between amino acidic gD sequences of HSV-1 HF and -2 MS affecting the 
IgG binding affinity.  The post-entry activity of the three antibody formats was then compared to 
their post-virus attachment activity using previously-described procedures (Burioni et al., 1994). In 
this case virus adsorption was performed at 4 °C, allowing the docking of virus anti-receptors with 
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cell receptors but impairing cell entry until the switch to 37 °C performed after the 4 °C addition of 
antibodies. Inhibition was observed for all tested antibody formats (Fig. S12), with no significant 
differences between the different formats for HSV-2 MS. Conversely, both IgG and scFv 
demonstrated better HSV-1 HF inhibition compared to the Fab#33. It is noteworthy that the assay 
performed at 4 °C resulted in inhibitory activity by the scFv format against both virus types, in 
contrast to the standard neutralisation assays. The exact processes underlying the mechanisms 
involved in mAb#33-mediated inhibition remain to be determined, but the inhibitory activity in 
post-entry assays of mAb#33 (especially scFv and IgG formats) was robust and reproducible. A 
possible explanation for the observed effect might be the different steric hindrance of IgG 
compared to the Fab format. Notwithstanding this, this is in over contrast with the behaviour of 
the scFv format in the same assay, which although lacking any neutralising activity featured a 
strong plaque area decreasing activity. An explanation of this paradoxical activity might be found 
in the possible mAb#33 interference of gD-mediated triggering of gB fusogenic activity. As 
suggested by the complete lack of neutralising activity by the scFv#33 it is probably directed 
against gD regions not directly involved in binding to cellular receptors. The observed neutralising 
activity of the Fab and the whole IgG formats may therefore only be an effect of increasing steric 
hindrance, inhibiting binding to the target cell. This specific feature was not directly addressed in 
the present paper but, in our opinion, certainly deserves further investigation, as far as mAb#33 
epitope definition is concerned. Two potential mechanisms have been described for the triggering 
of fusion by gD in its post-docking conformation. In one setting, gD exposes its PFD thus triggering 
gB already bound to its receptors (Cohen et al., 1986; Gallagher et al., 2014; 2013; Stampfer et al., 
2010). In the other, gD binds to its receptors causing displacement of the gD C-terminus to expose 
a previously hidden region, which then interacts to gH/gL dimer, leading to its activation. The 
dimer activated form subsequently interacts with gB regulating fusion process (Atanasiu et al., 
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2013; Gianni et al., 2015; Jackson et al., 2010). Although both mechanisms could be supported by 
the different functional behaviour of the three engineered formats of Hu-mAb#33, further 
dedicated studies are certainly needed to define its mechanisms of action and its epitope. 
Overall, the in vitro results and the interference with different phases of HSV spread suggested a 
potential application of mAb#33 in different HSV-related clinical manifestations. Given the higher 
in vitro efficacy against both HSV-1 and -2 laboratory strains of IgG#33 compared to its Fab and 
scFv antibody formats, we then tested its activity against different HSV-1 and -2 clinical isolates. 
IgG#33 possessed potent neutralising activity against these clinical isolates and, surprisingly, 
resulted in an even stronger post-entry reduction of plaque number and greater inhibition of 
plaque area against the tested isolates. Importantly, we observed that HSV-1 isolates, including 
the LV neurotropic isolate (Tognon et al., 1985), are more susceptible to IgG#33 than the 
previously tested lab strain HSV-HF. It is important to note that the viruses tested were isolated 
from different replication sites from patients affected by different HSV-1 and -2 clinical 
manifestations and featured different susceptibility to ACV. These findings pave the way to the 
possible use of IgG#33 to treat diverse clinical HSV manifestations that are not susceptible to ACV 
treatment. Importantly, the IgG#33 target is completely different and unrelated to that of ACV, 
highlighting the potential for therapeutic co-administration with “classical” drugs for the 
treatment of patients suffering for drug nephrotoxicity. Given the promising in vitro results, in vivo 
testing of IgG#33 was a logical progression of these studies. However, several mAbs able to 
neutralise HSV have been described so far. Most them are directed against viral gD or gB are 
murine (Däumer et al., 2011; Lazear et al., 2012; Minson et al., 1986; Muggeridge et al., 1990; 
Nicola et al., 1998), fewer are of human origin (Burioni et al., 1994; Lee et al., 2013). We decided 
to develop a human antibody to both minimise the risks of anti-IgG response and avoid Ab-
humanisation processes necessary for therapeutic mAb administration. It is well known that 
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repeatedly administering mAbs in humans may induce anti-idiotype and anti-allotype antibodies. 
However, these adverse effects were documented mostly when administering animal-derived 
antibodies, whereas humanised mAbs were well tolerated.  These side-effects do not occur for 
human monoclonal antibody administrations (De Logu et al., 1998; Knox et al., 1991).  In the case 
of HSV the most protective and best characterised human/humanised mAbs recognise virus gD or 
gB of both HSV-1 and -2 (Berdugo et al., 2012; Krawczyk et al., 2013; 2015; Lee et al., 2013; Sanna 
et al., 1996; Zeitlin et al., 1996; 1998). Among the most promising anti-gD mAbs are E317 and AC-
8.  The structural basis for recognition of gD antigen by the neutralising E317 Fab have been 
elucidated through co-crystallisation approaches. AC-8 is the only human anti-gD mAb tested on 
animals in different experimental settings. Topical administration of AC-8 in different antibody 
formats (Fab, F(ab’)2, IgG1) was tested by Zeitlin et al. (Zeitlin et al., 1996) concomitantly to HSV-2 
vaginal challenge, demonstrating for the first time the potential of topical passive immunisation 
with a human anti-gD mAb to both prevent lesions and reducing virus shedding. Another 
important advance was testing topical administration of AC-8 Fab against HSV-1 KOS corneal 
infection (Berdugo et al., 2012). The Fab was able to significantly limit disease and reduce virus 
titres within tear films, but was not as effective as trifluridine (TFT). Non-topical administration of 
anti-gD human IgG AC-8 protected SCID mice from both intra-cutaneous and ocular HSV-1 
challenge (Sanna et al., 1995). IgG AC-8 was administered intraperitoneally prior to, or after virus 
infection significantly prolonging mice survival. To date, intravenous systemic administration of 
human anti-gD antibodies has not been described. However, HSV generally causes viremia 
followed by severe sequelae only in circumscribed clinical settings such as immunocompromised 
patients or new-borns, therefore, an interesting option was to test intravenous single 
administration of IgG#33 before or after HSV-1 and -2 ocular and vaginal lethal challenge. In both 
prophylactic and therapeutic HSV-2 intravaginal infection experiments IgG#33 was injected at two 
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doses (5 and 15 mg/Kg) compatible with possible clinical use (Glassman and Balthasar, 2014). Both 
IgG doses fully protected mice from death in both experimental protocols. The main difference 
observed between these experiments was the greater reduction in virus titre in vaginal lavages 
from mice therapeutically treated with IgG#33, and the milder clinical signs compared to both 
control cohorts. However, in the prophylactic protocol the unrelated IgG partially protected mice 
from death at the end of experiments (8 days p.i.). Despite this, all the mice treated with the 
unrelated mAb control experienced greater disease progression in contrast with those treated 
with IgG#33, consistent with an increased virus titre (statistically significant only in the 
prophylactic experiment) measured in vaginal lavages of mice receiving the control IgG. An 
explanation for this partial protection from death but not from relevant clinical signs could be the 
immunogenic boost conferred to C57BL/6 immunocompetent mice by the systemic administration 
of mAbs before the virus challenge. A single systemic IgG#33 administration through lateral tail 
vein protected also mice challenged with both HSV types via corneal scraping. The protection 
against HSV-1 ocular challenge conferred by systemic mAb administration is consistent with 
previous studies using an anti-gB humanised antibody (Krawczyk et al., 2015). IgG#33 protected 
mice from both death and severe HSV clinical manifestations over all experimental durations. 
Moreover, all mice receiving IgG#33 that presented milder disease completely recovered during 
the follow-up period. In this experimental setup, the follow-up was 13 days p.i. for HSV-1 
challenged mice and 8 days p.i. for those infected with HSV-2. Due to the severe and very rapid 
development of irreversible clinical manifestations observed for mice not receiving IgG#33, the 
HSV-2 challenged mice were sacrificed according to ethical committee directives. Consistent with 
clinical scoring data, the analysis of viral infectious load in tear films collected from the different 
mice treated cohorts established that all mice receiving IgG#33 almost completely cleared both 
infective virions and HSV-1 and -2 genome copies. Virus clearance at day 7 p.i. was completely 
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independent of both the number of HSV genome copies detected and of viral titre of samples 
collected at day 2 p.i.. These assumptions are consistent with microscopic observations of infected 
eye cryosections in which, for both HSV-1 and -2 infected mice, it was possible to detect a 
considerable virus presence within the cornea scraped for virus challenge. Interestingly, in IgG#33-
treated eyes, large amounts of virus were constrained to primary infection site but very low 
detectable viruses were present within the retina and adjacent eye tissue layers. In contrast, very 
high amount of virus was present in cornea, retina and other eye tissue layers within the eye 
receiving IgG mock control, suggesting that unrelated IgG cannot block the spread of infection 
from cornea to adjacent tissues. This last observation is coherent with clinical depiction of eye 
disease scoring. Kidneys were dissected and stained in order to establish virus presence and tissue 
architecture in the different mice cohorts. Kidneys were chosen for immunohistochemistry 
because in this systemic infection model their evaluation in terms of both virus presence and 
tissue integrity provides insights related to antiviral/protective activity of the mAb during 
disseminated HSV infection. Last, kidneys can be explanted without damaging tissue integrity, 
differently for other organs such as brain that, in the case of last stage HSV-CNS involvement, 
completely loses its tissue consistency strongly impairing the sample cryosectioning. Confocal 
microscopy analysis of kidney cryosections revealed that only kidneys explanted from mouse 
receiving IgG#33 retained tissue integrity, with no evidence of virus in all internal kidney 
compartments. This observation is fully consistent with the total lack of severe systemic signs of 
HSV infection in mice treated with IgG#33. 
Together, these observations confirmed the potential for IgG#33 as a therapeutic for HSV 
infection, considering also that in humans the Fc-mediated effects could further improve IgG 
efficacy allowing for example the recruitment of cellular immunity, such as CD8+ T cels, which play 
pivotal roles in clearing HSV dissemination (van Lint et al., 2004). These data pave the way for 
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further studies investigating either the ability of IgG#33 to inhibit virus reactivations in vivo, or the 
presence of gD epitopes eliciting in vivo an IgG#33-like antibody response (Belshe et al., 2012; 
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FIGURES and CAPTIONS 
 
Fig. 1. Post-virus entry inhibition assays. (A) Evaluation of the ability of Fab#33 to decrease 
number of plaques compared to both HSV-1 HF and HSV-2 MS virus positive control in “post-entry 
assays”. (B) Evaluation of mean plaque area reduction for Fab#33 treated cells previously infected 
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with either HSV-1 HF or HSV-2 MS. Controls (AC-8 and unrelated negative control Fab) are 
included for all experiments. Percent reduction compared to the infection control is reported 
above each column (statistically significant p values obtained by comparing Fab#33 to Fab mock 
control, black asterisks, and Fab AC-8, red asterisks, ***p<0.001, **p<0.01). (C) Competition assay 
between Fab#33-FLAG and Fab AC-8 performed by FACS analysis of cells transfected with gD1. The 
table shows the differences in the number of gated cells and median due to competition between 
the two Fabs. Below, the signal controls of the different antibodies on gD1 transfected cells (red) 




Fig. 2. Post-entry assays for the comparison of inhibitory activity of scFv#33, Fab#33 and IgG#33. 
Bright-field optical microscopy pictures collected for cells treated with the three antibody formats. 
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Bar 500 μm, magnification 5x. Columns (left to right) show respectively virus positive infection 
controls and the three engineered mAb formats (scFv#33, Fab#33 and IgG#33). Inhibition of 
plaque number is indicated on second rows as “% infection inhibition” compared to an uninhibited 
positive control. Third rows depict plaque area means (expressed in µm2) and upper and lower 
95% CI from mean (above each column, the percentages indicating plaque area reduction 
compared to virus control is indicated). Hu-mAb#33 engineered molecular formats tested against 
HSV-1 HF (A) and HSV-2 MS (B). (statistically significant p values obtained by comparing mAb#33 
to mAb mock control, black asterisks, and Fab#33 to IgG#33 or scFv#33, red asterisks, 
****p<0.0001, ***p<0.001, **p<0.01, *p<0.05). 
 
 
Fig. 3. Evaluation of the ability of IgG#33 to inhibit replication of clinical HSV isolates after virus 
entry. Both LV (HSV-1, panel A) and #26 (HSV-2, panel B) clinical isolates were efficiently inhibited 
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by IgG#33 in in vitro post-virus entry assays. IgG#33 reduced both area and number of plaques 
compared to positive infection controls. From left to right: inhibition of plaque area by IgG#33. 
Mean of areas (± 95% CI) measured on differently treated infected cells are indicated. The values 
reported above each column indicate percentage reduction in plaque area compared to virus 
control. Then, inhibition of plaque number by IgG#33. Plaque number was compared to positive 
infection controls in the absence of inhibitor. A single concentration was used to compare the 
activity of IgG#33 against HSV clinical isolates (black boxes). (p-values obtained comparing IgG#33 




Fig. 4. Prophylactic and therapeutic activity of a single systemic injection of IgG#33 against HSV-
2 vaginal challenge. (A) Survival curves of the different treated groups (**p<0.01). (B) Clinical 
disease scoring indicated the mean index of clinical disease in the different mice groups, from day 
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5 to 8 p.i. Error bars within the graph indicate SEM (**p<0.01, *p<0.05). (C) Pictures taken at 8th 
day p.i. show examples of clinical presentation of mice receiving intravaginal HSV-2 challenge. (D) 
IN Cell Analyzer System analysis indicates the titres detected in vaginal lavages collected 48h p.i. 




Fig. 5. Therapeutic activity of a single systemic injection of IgG#33 against both HSV-1 and HSV-2 
ocular virus challenge. (A) Survival curves of the different treated groups (**p<0.01, *p<0.05). (B)  
Mean clinical disease scoring for all mice receiving different drug-regimens, from day 1 to 13 p.i. 
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and 1 to 8 p.i. for mice challenged with HSV-1 and HSV-2 respectively. SEM of the clinical scoring 
for each group is presented (***p<0.001, **p<0.01). (C) Images taken at day 7 p.i. highlight 
examples of clinical presentation of mice receiving ocular HSV-1 and HSV-2 challenge. (D) Graphs 
reporting IN Cell Analyzer System analysis and RT-PCR analysis indicated the titres in film tear 
lavages collected at day 2 and day 7 p.i., and the virus genome load for the same samples, 





Fig. 6. Immunohistochemical analysis of mouse tissues (A) Imaging of kidney sections after mouse 
sacrifice. Images (63-fold magnification) highlight different kidney cryosections (capsule, cortex, 
medulla and pelvis). Green fluorescence highlights F-actin bound by Phalloidin Alexa Fluor 488®, 
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red signal (anti-HSV1 + HSV2 gD antibody Alexa Fluor 546®) indicates virus presence and blue 
Hoechst signal highlights nuclei. For each row the virus used to perform the challenge, the 
treatment regimen and the clinical scoring of dissected animals are indicated. (B, C) 
Immunohistochemical analysis of HSV-1 infected mouse eyes after sacrifice. Ten-fold 
magnification pictures (merged images), displayed on the left, present an overview of the whole 
eye cryosection (lens axis). Panels (63-fold magnification) show different details of eyes. Green 
fluorescence highlights F-actin bound by Phalloidin Alexa Fluor 488® and red signal of anti-HSV1 + 
HSV2 gD antibody (Alexa Fluor 546®) indicates virus presence, blue Hoechst signal indicates nuclei. 
(B) Eye dissected from mouse receiving single systemic administration of IgG#33 (15mg/Kg). 
Panels indicate: extraocular muscles, corneal and conjunctive detached tissues, a and b; cornea 
and conjunctive, c and d; iris and ocular anterior chamber, e and f; retina, g to i. (C) Eye dissected 
from unrelated IgG (15mg/Kg) receiving mouse systemically administered after infection. Panels 
indicate: cornea and conjunctive, a and b; iris and ocular anterior chamber, c and d; extraocular 
muscles, corneal tissues, e and f; retina, g to i.  




Materials and Methods 
Cells and Viruses. Vero E6 (Vero C1008, clone E6 - ATCC® CRL-1586™) and HEK 293T (ATCC® CRL-
1586™) cells were both cultured in Dulbecco’s Modified Eagle Medium (Gibco® DMEM, 
ThermoFisher Scientific) containing 10% (v/v) fetal bovine serum (FCS, EuroClone), 100 U/mL 
penicillin and 0.1 mg/mL streptomycin (Gibco® ThermoFisher Scientific), 0.01 M HEPES (Gibco® 
ThermoFisher Scientific) and MEM Non-Essential Amino Acids (Gibco® ThermoFisher Scientific). 
The laboratory strains HSV-1 HF (ATCC® VR-260™) and HSV-2 MS (ATCC® VR-540™) were used. 
Clinical isolates HSV-1 #1 (oral cavity), #7 (bronchoalveolar lavage, BAL), #8 (pharyngeal swab) and 
#11 (vesicle), and HSV-2 #18 (cutaneous swab), #21 (vaginal discharge), #25 (vaginal swab), #26 
and #28 (both cutaneous swab) were kindly provided by Dr. R. Santangelo, Department of 
Microbiology, Università Cattolica del Sacro Cuore of Rome, Italy. HSV-1 LV neurovirulent strain 
has been described elsewhere (Tognon et al., 1985). (i) In vitro virus propagation and titration. 
These strains were expanded in semiconfluent T-25 flasks (Corning® CellBIND®) of Vero E6 cells. 
The cells were infected with HSV-1 or HSV-2 in complete DMEM without FBS, and after 2 h the 
medium was replaced with fresh complete DMEM with 2% FBS, and cultured for further 2 to 3 
days until cell lysis. Cell supernatants were then collected and, after clarification at 800 x g for 5 
min, stored in small aliquots at −80°C until use. For examination of virus titers the cell 
supernatants were tested on Vero E6 monolayers using plaque assay or IN Cell Analyzer System 
analysis (GE Healthcare IN Cell Analyzer 1000 System). Plaque titration of the viral stocks was 
carried out seeding the cells (1 × 105/well) in 24-well plates and the next day inoculated with 10-
fold dilutions (range, 10−2 to 10−6) of the viral stocks in duplicate. After 20 min, the medium was 
replaced with complete DMEM with 2% FBS and 1% Agarose (BD BaculoGold™ Plaque Assay 
Agarose) and the plates were incubated for 46 h. The cells were then fixed with 4% formaldehyde 
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solution in PBS for 1 h and stained with crystal violet, and viral plaques were counted. Titers are 
expressed as PFU/mL. IN Cell Analyzer System analysis of the viral stocks instead was carried out 
seeding Vero E6 cells (2.6 x 104/well) in 96-well plates and the next day inoculated with 10-fold 
dilutions (range, 10−1 to 10−8) of the viral stocks in triplicate. After 2 h, the medium was replaced 
with complete DMEM with 2% FBS and the plates were incubated for 21 h. The cells were then 
fixed with 1:1 solution of acetone/methanol and stained. Briefly, anti-HSV1 + HSV2 gD antibody 
[2C10] (ab6507, Abcam) and Goat anti-Mouse IgG (whole molecule)–FITC antibody (F0257, Sigma-
Aldrich) were used as primary and secondary antibody, respectively. Hoechst 33258 (Sigma-
Aldrich) was used for nuclear staining. Then IN Cell Analyzer System allowed high throughput 
acquisition of high quality images of the plates and its software counted the fraction of infected 
cells of each well. Titres are expressed as 50% Tissue culture Infective Dose (TCID50)/mL. (ii) In vivo 
viral inoculum effect. Since age and oestrous cycle are known to influence the susceptibility to 
genital, in vivo titration via vaginal challenge of HSV-2 MS viral stock was performed in mice at 11 
weeks of age, with their oestrous cycles synchronized (Teepe et al., 1990). Cycle synchronization 
was achieved with 2 mg of depot medroxyprogesterone acetate (Depo-Provera, Pfizer Italia) 
inoculated subcutaneously 5 days before infection. To facilitate virus absorption, the vaginas were 
pre-swabbed with a dry-tipped swab immediately prior to the instillation of 10-fold dilutions in 
DMEM of the viral stocks, pipetting 50 μL of virus dilution in mice vaginas under 2,2,2-
tribromoethanol general anaesthesia. The animals were then examined daily for signs of infection. 
These usually showed up at day 5 or 6 with local erythema and ulcers and rapidly evolved into 
manifestations of nervous system involvement (arched backs, feeble movements, and paralysis of 
one or both hind limbs). The latter stage was usually irreversible, and death occurred within 1 to 2 
days. HSV-1 LV and HSV-2 MS viral stocks were used for in vivo titration via ocular challenge as 
well. Under 2,2,2-tribromoethanol general anaesthesia, the right cornea was scarified with a 
45 
 
sterile glass Pasteur pipette. Four scratches were made to facilitate virus adsorption (Berdugo et 
al., 2012). A 5 μL drop of DMEM (2% serum) containing 10-fold dilutions of the viral stocks was 
applied to the scarified cornea. The eyelids were closed twice over the cornea, and the animals 
were returned to their cages. The animals were then examined daily for signs of infection as puffy 
eyelids, crusting, cloudiness, opaque or perforated cornea, swollen shut eye. These symptoms can 
resolve within few days, but if not they rapidly evolved into manifestations of nervous system 
involvement (arched backs, altered motor function), an irreversible stage. Animals that survived 
despite paralysis or other irreversible lesions were euthanized by cervical dislocation under 
anaesthesia. Thus, the lethal dose 50 (LD50) of both viruses was assessed for either protocols of 
infection. About 3 LD50 of each virus settings were used in therapeutic and prophylactic 
experiments.  The selected doses of both viruses for the different infection protocols resulted in 
an irreversible condition at day 8 p.i. for HSV-2 MS (both for vaginal and ocular challenge) and at 
day 13 p.i. for HSV-1 LV. Mice with mild symptoms or which recovered from disease were followed 
up for 20 days p.i. and no relevant differences in their conditions were observed. 
Patients’ sera evaluation for anti HSV reactivity. Sera were collected from 20 patients and tested 
for the reactivity against HSV-1 and HSV-2 performing an enzyme-linked immunosorbent assay 
(ELISA). Informed consent was obtained for all patients. Briefly, HSV-1 HF and HSV-2 MS strains 
were expanded in confluent T-25 flasks (Corning® CellBIND®) of Vero E6 cells. The cells were 
infected with viruses in complete DMEM without FBS, and after 2 h the medium was replaced with 
fresh complete DMEM with 2% FBS, and cultured for further 2 to 3 days until cell lysis. Cell 
supernatants were then collected and, after clarification at 800 x g for 5 min, heat-inactivated for 
30 min (HSV-1) or 10 min (HSV-1) at 56°C. Then the supernatants were used for overnight coating 
of 96-wells microplate (Corning® Costar®) at 4°C. Coating control with 1% Bovine Serum Albumin 
(BSA, Sigma-Aldrich) solution in PBS was added for not specific reactivity control. The following 
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day, the plate was blocked with 1% BSA solution in PBS to prevent not specific binding to wells and 
sera were incubated with antigens for 1 h at 37°C. After washing with 0.1% Tween 20 (Sigma-
Aldrich) in PBS solution, detection was with Goat Anti-Human IgG (Fab specific)−Peroxidase 
antibody (A0293, Sigma-Aldrich) and Pierce™ TMB Substrate Kit (ThermoFisher Scientific). 450 nm 
Optical Density (O.D.) was measured using Multiskan GO (ThermoFisher Scientific). The patient 
#18 whose serum showed higher reactivity was chosen for peripheral B cells collection. 
Generation and production of an anti-HSV human mAb (Hu-mAb). The preparation of human 
antibody Fab libraries displayed on the surface of M13 phage has been described (Galanis et al., 
2001). Briefly, peripheral B cells mRNAs codifying for Ab HCs and LCs was retro-transcribed in 
cDNA to construct phagemid library to be converted in phage library and panned for the selection 
of Fab fragments specific for the selected target. Following these procedures, Fab#33 was selected 
from peripheral blood B-lymphocytes of donor showing strong serum IgGs ELISA reactivity against 
both HSV-1 and 2 virus isolates. Antigens binding phages were selected against HSV-1 and HSV-2 
infected Vero E6 after a deselection step against uninfected cells. Phages from the final round of 
panning procedure were converted to a soluble Fab expressing phagemid system and Fab#33 was 
selected for its reactivity against both HSV-1 and HSV-2 infected cells. The antibody was affinity 
purified from E. coli supernatant over a column prepared with a Goat anti-Human IgG F(ab')2 
Secondary Antibody (ThermoFisher Scientific) bound to GammaBind G Sepharose medium (GE 
Healthcare) as described (Solforosi et al., 2012). 
scFv and IgG#33. Single chain mAb#33 (scFv) VL/VH was constructed as follows: variable light 
chain sequence (VL) and variable high chain (VH) sequences of Fab#33 were amplified using 
specific primers containing the linker sequence. In brief, overlapping primers for VL and VH were 
designed containing the 15-amino acid (Gly4Ser)3 flexible hinge region respectively at 3’ and 5’. 
The scFv sequence containing 3’ Hexa-His tag was then cloned into pCM expression vector 
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(Solforosi et al., 2012). The same procedure was adopted to generate control scFv (scFv e137). 
Primers:  Fw ScFv: CTTTAAGAAGGAGATATACCATGAAATACCTATTGCCTACGGCAGCCGC; Rev ScFv: 
AGAACCACCACCACCAGAACCACCACCACCTTTGATTTCCACCTTGG; Fw ScFv#33: 
GGTGGTGGTGGTTCTGGCGGCGGCGGCTCCGGTGGTGGTGGATCTCTCGAGTCTGGGGGAGGCGTG; Rev 
ScFv#33: CTCAGTGGTGGTGGTGGTGGTGCTTCGGTTCAGCAGGATCCTGGGAGGAGACGGTGACCAGG; 
Fw ScFve137: GCACGAGCCCGAGCTCACCCAGTCTCCATCCTTCCTGTCTGCATCTGTAG; Rev ScFve137: 
GAGAGAACTAGTTCAGTGGTGGTGGTGGTGGTGCTTCGGTTCAGCAGGATCCTGTGAGGAGACGATG. 
The antibodies were affinity purified from E. coli supernatant over a column prepared with Ni-NTA 
Agarose (QIAGEN). IgG#33 format was designed in our laboratory and the large-scale production 
was performed by GenScript® using MamPowerTM Antibody Production Service. 
Binding studies on infected cells. HSV-1 strain HF or HSV-2 strain MS (200 TCID50) was applied to 
Vero E6 cell monolayers grown in 96-wells plates. After 2 h, the medium was replaced with 
complete DMEM with 2% FBS and the plates were incubated for 21 h. The cells were then fixed 
with 1:1 solution of acetone/methanol and stained. Briefly, Fab#33, IgG#33 and scFv#33 were 
used as primary antibodies. Goat anti-Human IgG (H+L) Alexa Fluor® 488 (A-11013, ThermoFisher 
Scientific) was used to detect both Fab#33 and IgG#33, while Anti-6X His tag® antibody [HIS.H8] 
(ab18184, Abcam) and Goat anti-Mouse IgG (H+L) Alexa Fluor 546® (A-11030, ThermoFisher 
Scientific) were used for scFv detection. Hoechst 33258 (Sigma-Aldrich) was used for nuclear 
staining. Then images were acquired with Zeiss Axio Observer.Z1 microscope with QImaging Exi-
Blue (Carl Zeiss, Oberkochen, Germany) at a 20-fold magnification. 
Fab#33 target identification. (i) Western blotting. HSV-1 strain HF was expanded in Vero E6 cells 
semiconfluent T-75 flasks (Corning® CellBIND®). The flasks were infected with HSV-1 in complete 
DMEM without FBS, and after 2 h the medium was replaced with fresh complete DMEM with 2% 
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FBS, and cultured for further 6 days until complete cell lysis. Cell supernatants were then collected 
and placed at 56°C for 30 min for virus inactivation. After clarification at 8,000 x g for 10 min at 
4°C, the supernatants were loaded on a 5% (w/v) sucrose cushion and centrifuged at 100,000 x g 
for 1h at 4°C. The pellet containing the virus was then resuspended, loaded on a sucrose gradient 
(range, 10% to 60%) and centrifuged at 30,000 x g for 5h at 4°C. The purified virus was collected 
from the interface between 30% and 60% layers. The purified HSV-1 HF was resolved on a SDS-
PAGE (Bolt® 4-12% Bis-Tris Plus Gel, ThermoFisher Scientific) and electroblotted onto PVDF 
membrane in Transfer Buffer (25 mM Tris, 190 mM glycine, 20% methanol, 0.1 % SDS, pH 8.3). 
Western blot was prepared according to standard protocols. Briefly, blotted PVDF membrane was 
blocked with 5% non-fat dry milk in Tris-buffered saline (TBS) and probed with Fab#33, anti-HSV1 
+ HSV2 gD antibody [2C10] and anti-HSV1 + HSV2 gB antibody [10B7] (ab6506, Abcam) in 1% non-
fat dry milk in TBS containing 0.1% Tween 20. Detection was with a Goat Anti-Human IgG (Fab 
specific)−Peroxidase antibody (A0293, Sigma-Aldrich) for Fab#33, and with a Goat Anti-Mouse IgG 
(whole molecule)–Peroxidase antibody (A4416, Sigma-Aldrich) for control antibodies, and 
SuperSignal® West Pico Chemiluminescent Substrate (ThermoFisher Scientific). (ii) HSV-1 gD and 
gB gene cloning and transient transfection of HEK 293T cells. HSV-1 infected Vero E6 cells 
supernatant was used for virus DNA extraction (QIAamp MinElute Virus Spin Kit, QIAGEN) and full 
length (residues 1 - 394) gD1 was cloned into mammalian expression vector (pcDNATM 3.1 
Directional TOPO® Expression Kit, Invitrogen). Full length (residues 1 - 904) glycoprotein B gene of 
HSV-1 strain HF (gB1) was synthesised and cloned into mammalian expression vector pcDNA3.1 (+) 
by Gene Synthesis Service of Genscript®. HEK 293T cells were seeded (4x105/well) in 6-wells plate 
and the next day transfected with the gD1-expression vector or gB1-expression vector and 
Lipofectamine® 2000 Transfection Reagent (ThermoFisher Scientific) in Opti-MEM® Reduced Serum 
Medium (Gibco®, ThermoFisher Scientific). 6 h later the medium was replaced with serum-free 
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DMEM without antibiotics and the transgene expression was tested after 48 h. The cells were 
harvested and, after washing twice with Phosphate-Buffered Saline (PBS Gibco®, ThermoFisher 
Scientific) at 200 x g for 5 min, spun onto microscope slides by use of a cytocentrifuge at 91 x g for 
3 min. The cells were then fixed with 1:1 solution of acetone/methanol and stained. In details, 
anti-HSV1 + HSV2 gD antibody [2C10] and anti-HSV1 + HSV2 gB antibody [10B7] were used as 
positive control and detected with Goat anti-Mouse IgG (H+L) Alexa Fluor 546® (A-11030, 
ThermoFisher Scientific). Fab#33 was used as primary antibody and Goat anti-Human IgG (H+L) 
Alexa Fluor® 488 (A-11013, ThermoFisher Scientific) was used for its detection. Nuclei were stained 
using Hoechst 33258 (Sigma-Aldrich). The images were acquired with Zeiss Axio Observer.Z1 
microscope with QImaging Exi-Blue (Carl Zeiss, Oberkochen, Germany) at a 20-fold magnification. 
Phenotypic assay for the evaluation of ACV susceptibility. The assay already described by Leary 
(Leary et al., 2002) was used following the procedure to perform PRA above described. In brief, 
after virus entry, different concentration of acyclovir (Acycloguanosine, ACV, Sigma-Aldrich) were 
used in solid agarose medium (agarose concentration 1%). 
Post-attachment neutralisation assay. 100 PFU of HSV-1 HF or HSV-2 MS were added at 4°C Vero 
E6 cell monolayers, pre-chilled at 4°C for 15 min. After 90 min, the inoculum was removed and 
serial dilutions of the different antibody formats in DMEM were added at 4°C. After 90 min, 
medium was replaced with complete DMEM with 2% FBS and 1% Agarose (BD) and plates were 






Fig. S1. ELISA assays. 20 different human sera tested against lysate HSV-1 and HSV-2 infected Vero 
E6 cells coated on 96-wells flat bottom microtiter plates. Patient 18 was chosen as source of 







Fig. S2. Binding studies performed on HSV infected cells. (A) Vero E6 cells infected with either 
HSV-1 HF or HSV-2 MS ATCC strains (left to right). Blue and green signals highlight cell nuclei and 
Fab#33 selective binding to infected cells, respectively (B) Similar IIF analysis performed with 
IgG#33 and scFv#33 engineered molecular formats of Hu-mAb#33. Blue signal highlights cell 
nuclei, green and red signals indicate the specific binding to HSV-1 and 2 infected cells of IgG#33 
and scFv#33, respectively. (Magnification 20x).   
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A              B 
 
Fig. S3. Fab#33 target identification. (A) HSV-1 purified virus SDS-PAGE followed by WB analysis 
using Fab#33 and commercial mAb controls. The three lanes are stained as follows: (1) murine 
anti-HSV gD commercial control, (2) murine anti-HSV gB commercial control, (3) Fab#33. The WB 
reactivity pattern of Fab#33 (lane 3) is comparable with that of anti-gD monoclonal Ab (lane 1), 
indicating that they recognise virus protein featuring the same molecular weights. The anti-gB 
mAb control detects virus gB at its different molecular weights. Both gD and gB molecular weights 
detected in WB analysis are coherent to literature data (58 kDs monomeric gD, 116 kDs dimeric 
gD) (Cohen et al., 1986). (B) IIF analysis on gD and gB expressing HEK 293T cells. Cells transfected 
with gD1 (upper row) and gB1 (lower row). Green signal indicates Fab#33 selective binding to gD1 
expressing cells. No green signal detected for Fab#33 on gB1 expressing cells. Red signals show 
selective binding of commercially available controls to gD1 and gB1 proteins. Blue signal highlights 




Fig. S4. Neutralisation assays performed using two techniques. Fab#33 neutralising activity 
evaluated against both HSV-1 and 2 laboratory strains (HF and MS respectively). Neutralisation 
tests were performed in triplicate using two approaches: micro-neutralisation assay followed by 
automated count and plaque assay. The black boxes indicate the IC50 calculated for Fab#33 against 
the two tested viruses to compare the two techniques. Percentage neutralisation was obtained by 
comparing the number of plaques or immunofluorescent infectious foci resulting from 
neutralisation mix infection (Fab#33/virus) of Vero E6 cells to number of infection events counted 




Fig. S5. Neutralising activity of different Hu-mAb#33 engineered formats. Serial dilutions of 
scFv#33, Fab#33 and IgG#33 were tested against two laboratory HSV isolates of type 1 and 2 (HF 
and MS). Micro-neutralisation assays followed by automated count analysis allowed calculation of 






Fig. S6. Neutralising activity of IgG#33 vs HSV clinical isolates featuring different susceptibility to 
ACV in vitro. Serial IgG#33 concentrations were tested against five HSV clinical isolates of type 1 
(LV, #1, #7, #8 and #11) and five of type 2 (#18, #21, #25, #26 and #28). HSV-1 and 2 laboratory 
strains (HF and MS) are given for comparisons (black boxes). Micro-neutralisation assay followed 








Fig. S7. Post-virus entry assays. Bright-field optical microscopy pictures collected for cells treated 
with the virus alone (positive infection control) and negative controls. Overview on the lack of 
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inhibitory activity of the experimental controls compared to HSV positive infection controls. Bar 
500 μm, magnification 5x. Columns (left to right) show respectively virus positive infection 
controls and negative controls. Inhibition of plaque number is indicated as “% infection inhibition” 
on second rows. Third rows depict plaque area means (expressed in µm2) and upper and lower 
95% CI from mean (above each column, the percentages indicating plaque area reduction 










Fig. S8. Plaque assays. scFv#33, Fab#33 and IgG#33 tested in post-virus entry assays in order to 
evaluate mean reduction of plaque number and areas compared to positive infection control. The 




Fig. S9. Phenotypic assay on Vero E6 cells for evaluation of acyclovir susceptibility of different 
HSV-1 and HSV-2 clinical isolates. Susceptibility to ACV is represented on the y-axis (expressed in 
percentage and normalised to number of plaques of tested isolates on Vero E6 cells without ACV) 





Fig. S10. LD50 for HSV-1 and HSV-2 in all experimental settings. The lethal dose 50 (LD50) of both 
HSV-1 and-2 viruses was assessed for either protocols of infection. Both virus types determine an 
irreversible condition at day 8 p.i. for HSV-2 MS (both for vaginal and ocular challenge) and at day 






Fig. S11. Immunohistochemical analysis of HSV-2 infected mice eyes after sacrifice. 10-fold 
magnification pictures (merge of pictures), 1st and 2nd on the left, show an overview of the whole 
eye lens axis cryosection for eye of IgG#33 treated mouse receiving single systemic injection (15 
mg/Kg) and Listing’s plane cryosection for eye of IgG control (15 mg/Kg) treated mouse. Green 
fluorescence highlights F-actin bound by Phalloidin Alexa Fluor 488®, red signal (anti-HSV1 + HSV2 





Fig. S12. Post virus attachment assay. Two concentrations of ScFv#33, Fab#33 and IgG#33 were 
tested against HSV-1 HF and HSV-2 MS in post virus attachment assay performed at 4°C. 
Statistically significant differences were observed when comparing mAb#33 to mAb mock control, 





Fig. S13.  gD1 and gD2 amino acid sequences alignment. Alignment of HSV-1 HF glycoprotein D 
sequence (GenBank: ABI63524.1) and HSV-2 MS glycoprotein D (GenBank: EU445527.1). 
Differences are highlighted in blue. 
